Almirall starts the year with solid growth

The first quarter was a good one for Almirall, and the new CEO hopes to live up to the 2021 guidance with the help of two potential EU approvals.

Photo: Almirall / PR

During the first three months of the year, Almirall has generated EUR 215m in sales, although only a small portion of this was in the dermatology business, where Almirall competes with Leo Pharma.

Here, sales grew from EUR 86m to just under EUR 89m.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs